Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3813-3822

  Giuliano, Sandy ^a,b   Cheli, Yann ^a,b   Ohanna, Mickaël ^a,b   Bonet, Caroline ^a,b   Beuret, Laurent ^a,b   Bille, Karine ^a,b   Loubat, Agnès ^b,d   Hofman, Véronique ^b,e   Hofman, Paul ^b,e   Ponzio, Gilles ^b,d   Bahadoran, Philippe ^c   Ballotti, Robert ^a,b   Bertolotto, Corine ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d Institut National de la Sante et de la Recherche Medicale U895   (France)

^e Human Biobank   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PROTEIN P53;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CELL AGING; CELL GROWTH; CELL LINEAGE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; GENE SILENCING; HUMAN; HUMAN TISSUE; MELANOMA CELL; MITOSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL AGING; CELL LINE, TUMOR; CELL LINEAGE; DNA DAMAGE; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MITOSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77951743475     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2913     Document Type: Article

References (50)

1. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. 15-year quest in search for MITF target genes. Pigment Cell Melanoma Res 2010;23:27-40.
2. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-122
3. Halaban R, Krauthammer M, Pelizzola M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009;4:e4563.
4. Yokoyama S, Feige E, Poling LL, et al. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 2008;21:457-463 (Pubitemid 351990971)
5. Carreira S, Goodall J, Denat L, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 2006;20: 3426-3439 (Pubitemid 44969160)
6. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-576 (Pubitemid 40017700)
7. Kido K, Sumimoto H, Asada S, et al. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation. Cancer Sci 2009;100:1863-1869
8. Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, Vucic D. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res 2008;68:3124-3132
9. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-718 (Pubitemid 34722267)
10. Nakai N, Kishida T, Shin-Ya M, et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 2007;14:357-365 (Pubitemid 46231929)
11. Schwahn DJ, Timchenko NA, Shibahara S, Medrano EE. Dynamic regulation of the human dopachrome tautomerase promoter by MITF, ER-α and chromatin remodelers during proliferation and senescence of human melanocytes. Pigment Cell Res 2005;18:203-213
12. Larribere L, Hilmi C, Khaled M, et al. The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev 2005;19:1980-1985 (Pubitemid 41247956)
13. Bertolotto C, Abbe P, Hemesath TJ, et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 1998;142:827-835 (Pubitemid 28381498)
14. Khaled M, Larribere L, Bille K, Ortonne JP, Ballotti R, Bertolotto C. Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J Invest Dermatol 2003; 121:831-836 (Pubitemid 37239128)
15. Hilmi C, Larribere L, Giuliano S, et al. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 2008;128:1499-1505 (Pubitemid 351693181)
16. Larribere L, Khaled M, Tartare-Deckert S, et al. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 2004;11:1084-1091 (Pubitemid 39341634)
17. Acilan C, Potter DM, Saunders WS. DNA repair pathways involved in anaphase bridge formation. Genes Chromosomes Cancer 2007;46: 522-531 (Pubitemid 46649567)
18. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-5868
19. Ward IM, Minn K, van Deursen J, Chen J. p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol 2003;23:2556-2563 (Pubitemid 36351034)
20. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007;26:7773-7779 (Pubitemid 350242463)
21. Shiotani B, Zou L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol Cell 2009;33:547-558
22. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003;63:6008-6015
23. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644-7655
24. 15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle 2008;7:3048-3055
25. KortleverRM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006;8:877-884 (Pubitemid 44151592)
26. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-3151
27. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;113:703-716 (Pubitemid 36724935)
28. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-319 (Pubitemid 39361432)
29. Zhuang D, Mannava S, Grachtchouk V, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008;27:6623-6634
30. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007;104: 13028-13033 (Pubitemid 351737587)
31. Bandyopadhyay D, Curry JL, Lin Q, et al. Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell 2007;6: 577-591 (Pubitemid 47087062)
32. Collado M, Medema RH, Garcia-Cao I, et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 2000;275:21960-21968 (Pubitemid 30621769)
33. Freedman DA, Folkman J. CDK2 translational down-regulation during endothelial senescence. Exp Cell Res 2005;307:118-130 (Pubitemid 40732738)
34. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007;21:43-48 (Pubitemid 46089705)
35. Li J, Stern DF. Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem 2005;280:12041-12050 (Pubitemid 40418523)
36. Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci U S A 2008;105:7785-7790 (Pubitemid 351872716)
37. Ho JS, Ma W, Mao DY, Benchimol S. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 2005;25:7423-7431
38. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005;37:961-976
39. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006;95:496-505.
40. Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005;433:764-769
41. Prince S, Carreira S, Vance KW, Abrahams A, Goding CR. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res 2004;64:1669-1674
42. Viale A, De Franco F, Orleth A, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009;457:51-56
43. De Petro G, Copeta A, Barlati S. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. Exp Cell Res 1994;213:286-294
44. Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX, Monboisse JC. In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 2004;301:251-265
45. Eymin B, Haugg M, Droin N, Sordet O, Dimanche-Boitrel MT, Solary E. p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999;18:1411-1418
46. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001;21:2144-2153
47. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005;37:745-749
48. Yu H, McDaid R, Lee J, et al. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol 2009;174:2367-2377
49. Brantley MA, Jr., Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000;157:1795-1801
50. Essner R, Kuo CT, Wang H, et al. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 1998;82:309-316